NASDAQ$CRON

Cronos Group Inc · Q4 2020 earnings

Q4 2020 earnings · · Investor relations

Briefing

Cronos Group's Q4 2020 results reflected hard work and perseverance, with revenue growth driven by the adult-use market in Canada, sales in the Israeli medical market, and growth in the U.S. segment, partially offset by strategic price reductions in Canada.

Cronos Group's Q4 2020 net revenue increased by $9.7 million compared to Q4 2019, primarily driven by growth in the adult-use market in Canada, sales in the Israeli medical market, and growth in the U.S. segment. The company's gross loss decreased by $5.2 million year-over-year, while the adjusted EBITDA loss increased by $1.5 million.

  • Net revenue of $17.0 million in Q4 2020 increased by $9.7 million from Q4 2019.
  • Gross loss of $14.9 million in Q4 2020 decreased by $5.2 million from Q4 2019.
  • The Company incurred an inventory write-down in Q4 2020 of $15.0 million on dried cannabis and cannabis extracts.
  • Adjusted EBITDA loss of $53.1 million in Q4 2020 increased by $1.5 million from Q4 2019.

Headline financials

Total Revenue

$17M

Previous: $7.31M+133.3%
EPS (adj)

-$0.31

Previous: $0.16-293.7%
Capital Expenditures

$11M

Previous: $757K+1353.1%
Free Cash Flow

-$47.9M

Previous: -$54.3M+11.8%
Net Income

-$112M

Previous: $61.6M-281.4%
Operating Income

-$58.4M

Previous: -$63.9M+8.5%
Gross Profit

-$14.9M

Previous: -$20.4M+26.9%
Cash & Equivalents

$1.08B

Previous: $1.2B-10.1%
Total Assets

$1.93B

Previous: $2.09B-7.9%
Stock-Based Comp

$2.46M

Previous: $3.67M-32.9%

Revenue & EPS history

Cronos · Revenue · Quarterly

$17M

Q4 2020+133.3%vs Q4 2019
Beat estimate in 5 of 9 quarters(56%)
ActualEstimate

Revenue by segment

Cronos · $17M total across 2 segments · Q4 2020

  • Israel and Other
    $13.5M+193.4%
  • Canada
    $3.51M+30.2%

Forward guidance

Cronos Group did not provide specific financial guidance for future periods in this earnings report.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2020

Historical avgQ4 2020

-1.8%

Avg return

Earnings day

-1.4%

Avg return

5 days after

+3.8%

Avg return

30 days after

34%

13 / 38 earnings

Positive

+35.6%

Q3 2020

Best reaction

-19.2%

Q2 2020

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+7.5%+3.1%+7.5%
Q4 2025-3.6%-6.1%-9.7%
Q3 2025+0.4%+2.9%+1.6%
Q1 2025+8.2%+10.3%+7.0%
Q4 2024+8.1%+9.2%-3.2%
Q3 2024+10.2%+2.0%-0.5%
Q2 2024-0.9%+5.0%-3.6%
Q1 2024+7.4%+13.6%-5.8%
Q4 2023-10.6%-12.8%+15.5%
Q3 2023+4.2%+6.3%+11.1%
Q2 2023-3.8%-5.5%+13.7%
Q1 2023-5.5%-13.1%-14.6%
Q4 2022+1.0%+1.0%-10.0%
Q3 2022-10.1%-1.0%-6.2%
Q2 2022-15.4%-11.5%-14.5%
Q1 2022+5.3%+15.5%-0.4%
Q4 2021-1.4%-10.9%+8.7%
Q3 2021-11.1%-12.1%-4.7%
Q2 2021-2.6%-6.6%-12.3%
Q1 2021-4.3%-6.0%+13.0%
Q4 2020+2.2%-4.4%-13.9%
Q3 2020+35.6%+31.2%+55.8%
Q2 2020-19.2%-20.5%-22.8%
Q1 2020-5.7%-13.4%+18.1%
Q4 2019-9.9%+3.0%+7.6%
Q3 2019-10.1%-22.3%-9.7%
Q2 2019-7.4%-3.5%-17.3%
Q1 2019-0.4%-1.4%+3.1%
Q4 2018-11.2%-10.2%-19.5%
Q3 2018-3.9%+1.3%+34.7%
Q2 2018+9.4%+12.2%+73.4%
Q4 2017-8.5%+4.1%+18.1%
Q1 2018-7.9%-5.0%+5.6%
Q3 2017-7.2%
Q2 2017+1.3%
Q1 2017-5.1%
Q4 2016-0.9%
Q3 2016-1.6%
Q2 2016
Q1 2016
Q4 2015
Q3 2015
Q2 2015
Q1 2015
Q3 2014
Q2 2014
Q3 2013
Q2 2013

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro